Ono Pharmaceutical (OTCMKTS:OPHLF) Reaches New 52-Week Low – Here’s Why

Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLF)’s stock price reached a new 52-week low during trading on Thursday . The stock traded as low as $9.22 and last traded at $9.22, with a volume of 20200 shares changing hands. The stock had previously closed at $10.51.

Ono Pharmaceutical Trading Down 12.3 %

The company has a 50-day simple moving average of $10.46 and a 200 day simple moving average of $12.57. The firm has a market cap of $4.33 billion, a PE ratio of 6.88 and a beta of 0.59.

Ono Pharmaceutical (OTCMKTS:OPHLF) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.24 EPS for the quarter. Ono Pharmaceutical had a return on equity of 11.80% and a net margin of 19.64%. The firm had revenue of $824.42 million for the quarter.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.